Medplus Health Services' subsidiary, Optival Health Solutions, received 7-day drug license suspension orders for two stores in Andhra Pradesh due to alleged rule violations. The estimated revenue loss is minimal at ₹2.92 lakh.
Medplus Health Subsidiary Faces Temporary License Suspension in Andhra Pradesh
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services Ltd, has been issued orders for the temporary suspension of drug licenses at two of its store locations in Andhra Pradesh. Reader Takeaway: Regulatory compliance issue at two stores; minimal revenue impact from temporary suspension. ## What just happened Medplus Health Services announced that its subsidiary, Optival Health Solutions Private Limited, received orders suspending drug licenses for seven days at two stores: one on Kovvada Main Road and another on Bethemcherla Main Road. The suspensions are due to alleged violations of Rule 65 of the Drugs and Cosmetics Act, 1940, and its associated rules. ## Why this matters The temporary closure of these two outlets is expected to result in a minor revenue loss of approximately ₹0.0292 crore (₹2.92 lakh) in total. While the financial impact is limited, this regulatory action highlights compliance challenges within the subsidiary's operations. ## The backstory Medplus Health Services is a leading pharmacy retail chain in India. Optival Health Solutions operates as its subsidiary, managing various health and wellness services. The Drugs and Cosmetics Act, 1940, and its rules govern the manufacturing, sale, and distribution of drugs in India, with stringent compliance requirements for licensed pharmacies. ## What changes now The two affected stores will be temporarily non-operational for seven days. Post-suspension, the stores are expected to resume operations, provided all regulatory requirements are met. The company has disclosed this information as per SEBI listing regulations. ## Risks to watch While the current financial impact is small, investors should monitor for any potential escalation of regulatory scrutiny or a pattern of non-compliance within the company's operations. Any further or more severe regulatory actions could pose a greater risk. ## Peer comparison Pharmacy retail chains in India operate under strict regulatory oversight. Similar minor compliance issues leading to temporary suspensions have occurred across the sector, typically involving documentation or operational adherence to the Drugs and Cosmetics Act. ## Context metrics (time-bound) * **Suspension Period:** 7 days for each store. * **Total Estimated Revenue Loss:** ₹0.0292 crore (₹2.92 lakh). * **Order Dates:** Received on June 23, 2026 (Kovvada Main Road) and issued by Kurnool & Nandyal District authority (Bethemcherla Main Road). ## What to track next Investors should track the successful resumption of operations at the affected stores after the suspension period and whether any further regulatory actions or clarifications are issued by the authorities.
